Go Deep
Supriya Lifescience Limited
Supriya Lifescience Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,897 | 35.2 | 5.83 | 0.01 | 867.45 |
Supriya Lifescience Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,897,470,000.0 | 2,765,280,000.0 | 2,064,400,000.0 | 1,998,330,000.0 |
| Net Profit | 240,430,000.0 | 742,290,000.0 | 496,750,000.0 | 504,270,000.0 |
| EPS | 3.0 | 9.2 | 6.2 | 6.3 |
Supriya Lifescience Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 8,023,650,000.0 | 6,795,640,000.0 | 5,574,100,000.0 | 4,510,150,000.0 | — |
| Net Profit | 2,091,200,000.0 | 1,879,570,000.0 | 1,191,140,000.0 | 898,570,000.0 | — |
| EPS | 26.0 | 23.4 | 14.8 | 11.2 | — |
Supriya Lifescience Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 13,571,070,000.0 | 11,173,470,000.0 | 9,214,480,000.0 | 8,202,770,000.0 | — |
| Total Liabilities | 1,593,740,000.0 | 1,205,870,000.0 | 1,060,810,000.0 | 1,208,186,000.0 | — |
| Total Equity | 11,977,330,000.0 | 9,967,600,000.0 | 8,153,660,000.0 | 6,994,580,000.0 | — |
Owes vs Owns
Supriya Lifescience Limited owed ₹0.12 for every ₹1 it owned in Mar 2026, down from ₹0.15 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.12× | 0.11× | 0.12× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Supriya Lifescience Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 5.8%Receivables 16.2%Inventory 11.8%Fixed assets (tangible) 53.3%Long-term investments 6.6%Other assets 6.2%
How it's funded — Mar 2026
Payables 8.2%Other liabilities 3.6%Shareholders' equity 88.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 78.8 | 79.1 | 75.0 | 154.4 |
| Receivables | 219.4 | 134.4 | 111.7 | 84.7 |
| Inventory | 159.6 | 118.3 | 85.2 | 115.8 |
| Fixed assets (tangible) | 723.4 | 609.3 | 457.3 | 328.1 |
| Intangible assets | 1.3 | 1.4 | 1.7 | 1.0 |
| Long-term investments | 90.0 | 57.0 | 61.1 | 25.1 |
| Other assets | 84.5 | 117.9 | 129.5 | 111.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 16.6 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 110.8 | 74.5 | 59.6 | 64.2 |
| Other liabilities | 48.5 | 46.0 | 46.5 | 40.0 |
| Shareholders' equity | 1,197.7 | 996.8 | 815.4 | 699.5 |
| Net tangible assets | 1,196.4 | 995.4 | 813.7 | 698.4 |
Supriya Lifescience Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 1,857,690,000.0 | 1,646,750,000.0 | 1,133,070,000.0 | 636,050,000.0 | — |
| Investing Activities | -1,761,740,000.0 | -1,522,440,000.0 | -1,735,740,000.0 | -1,236,540,000.0 | — |
| Financing Activities | -98,820,000.0 | -82,330,000.0 | -223,590,000.0 | -102,760,000.0 | — |